- Home
- PHAR
PHAR
Pharming Group N.V.
as 07-26-2024 4:00pm EST
Upcoming Earnings Alert:
Get ready for potential market movements as Pharming Group N.V. PHAR prepares to release earnings report on 01 Aug 2024.
| Founded: | 1988 | Country: | Netherlands |
| Employees: | N/A | City: | N/A |
| Market Cap: | N/A | IPO Year: | N/A |
| Target Price: | $37.00 | AVG Volume (30 days): | 3.0K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.20 | EPS Growth: | N/A |
| 52 Week Low/High: | $6.97 - $16.71 | Next Earning Date: | 08-01-2024 |
| Revenue: | $280,827,174 | Revenue Growth: | 28.19% |
| Revenue Growth (this year): | 23.66% | Revenue Growth (next year): | 15.25% |
Latest Pharming Group N.V. News
PHAR Breaking Stock News: Dive into PHAR Ticker-Specific Updates for Smart Investing
GlobeNewswire
9 days ago
Pharming Group to report second quarter and first half 2024 financial results on August 1
Yahoo Finance Video
2 months ago
FDA panel votes to recommend Eli Lilly's Alzheimer's drug
GlobeNewswire
2 months ago
Chu Vision Institute Unveils Comprehensive Guide to LASIK Recovery and Aftercare, Pioneering Patient Care in Minneapolis
Reuters
2 months ago
California seeks company profits in Big Oil climate lawsuit
USA TODAY
2 months ago
S&P 500, Nasdaq post record closing highs; Fed meeting, CPI ahead
GlobeNewswire
2 months ago
Ipsen’s Iqirvo® receives U.S. FDA accelerated approval as a first-in-class PPAR treatment for primary biliary cholangitis
Business Wire
2 months ago
Dutch Bros Inc. Announces Launch of Secondary Public Offering of Class A Common Stock
GlobeNewswire
2 months ago
Global Polycaprolactone Market to Record Revenue Worth US$ 1535.5 Mn by 2034; Anticipated to Experience CAGR of 10.3% During 2024 – 2034; states TNR, The Niche Research
Compare PHAR vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "PHAR Pharming Group N.V. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.